DUBLIN, July 8 /PRNewswire-FirstCall/ -- Amarin Corporation plc announced today it has sent to its shareholders a Notice of the Annual General Meeting of the Company, which will be held on July 31, 2008.
Copies of the Notice, together with the Company’s Annual Report for the year ended December 31, 2007 and the proposed new Articles of Association of the Company referred to in the Notice are available on the Company’s website at http://www.amarincorp.com. Shareholders may receive a hard copy of the Annual Report and the proposed new Articles of Association of the Company free of charge by contacting Investor Relations at the Company on +353-1669-9020 or investor.relations@amarincorp.com.
Amarin’s Annual Report for the year ended December 31, 2007 on Form 20-F was filed with the U.S. Securities and Exchange Commission on May 19, 2008.
About Amarin
Amarin is a biopharmaceutical company focused on improving the lives of patients suffering from cardiovascular and central nervous system (CNS) diseases. Amarin’s cardiovascular programs capitalize on the known therapeutic benefits of essential fatty acids in cardiovascular disease. Amarin’s CNS development pipeline includes programs in myasthenia gravis, Huntington’s disease, Parkinson’s disease, epilepsy and memory. Amarin also has two proprietary technology platforms: a lipid-based technology platform for the targeted transport of molecules through the liver and/or to the brain, and a unique mRNA technology based on cholinergic neuromodulation. Amarin has its primary stock market listing in the U.S. on the NASDAQ Capital Market (“AMRN”).
Disclosure Notice
The information contained in this document is as of July 8, 2008. Amarin assumes no obligation to update any forward-looking statements contained in this document as a result of new information or future events or developments. This document contains forward-looking statements about Amarin’s financial condition, results of operations, business prospects and products in research that involve substantial risks and uncertainties. You can identify these statements by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “project”, “forecast”, “intend”, “plan”, “believe” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or events. Among the factors that could cause actual results to differ materially from those described or projected herein are the following: Amarin’s ability to maintain sufficient cash and other liquid resources to meet its operating and debt service requirements; the success of Amarin’s research and development activities; decisions by regulatory authorities regarding whether and when to approve Amarin’s drug applications, as well as their decisions regarding labeling and other matters that could affect the commercial potential of Amarin’s products; the speed with which regulatory authorizations, pricing approvals and product launches may be achieved; the success with which developed products may be commercialized; competitive developments affecting Amarin’s products under development; the effect of possible domestic and foreign legislation or regulatory action affecting, among other things, pharmaceutical pricing and reimbursement, including under Medicaid and Medicare in the United States, and involuntary approval of prescription medicines for over-the-counter use; Amarin’s ability to protect its patents and other intellectual property; claims and concerns that may arise regarding the safety or efficacy of Amarin’s product candidates; governmental laws and regulations affecting Amarin’s operations, including those affecting taxation; risks relating to the Company’s ability to maintain its Nasdaq listing; general changes in International Financial Reporting Standards; and growth in costs and expenses. A further list and description of these risks, uncertainties and other matters can be found in Amarin’s Form 20-F for the fiscal year ended December 31, 2007, filed with the SEC on May 19, 2008.
CONTACT: Contacts: Amarin +353(0)1-669-9020, Thomas Lynch, Chairman and
Chief Executive Officer; Alan Cooke, President and Chief Operating Officer;
Darren Cunningham, EVP Strategic Development and Investor Relations,
investor.relations@amarincorp.com
